MacroGenics Plunges 73% After Interim Data Reveals Troubling Results for Vobramitamab Study
Silver Spring, Maryland – MacroGenics Inc (NASDAQ: MGNX) faced a significant blow on Friday as their shares plummeted over 50% following the release of interim data from the TAMARACK Phase 2 study. This study focused on vobramitamab duocarmazine (vobra duo), targeting B7-H3, an antigen prevalent in various solid tumors. The study specifically involved previously treated … Read more